FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080552198> ?p ?o ?g. }

• W3080552198 abstract "BACKGROUND AND OBJECTIVES: Historically, autosomal recessive 5q-linked spinal muscular atrophy (SMA) has been the leading inherited cause of infant death. SMA is caused by the absence of the SMN1 gene, and SMN1 gene replacement therapy, onasemnogene abeparvovec-xioi, was Food and Drug Administration approved in May 2019. Approval included all children with SMA age &lt;2 years without end-stage weakness. However, gene transfer with onasemnogene abeparvovec-xioi has been only studied in children age ≤8 months. METHODS: In this article, we report key safety and early outcome data from the first 21 children (age 1–23 months) treated in the state of Ohio. RESULTS: In children ≤6 months, gene transfer was well tolerated. In this young group, serum transaminase (aspartate aminotransferase and alanine aminotransferase) elevations were modest and not associated with γ glutamyl transpeptidase elevations. Initial prednisolone administration matched that given in the clinical trials. In older children, elevations in aspartate aminotransferase, alanine aminotransferase and γ glutamyl transpeptidase were more common and required a higher dose of prednisolone, but all were without clinical symptoms. Nineteen of 21 (90%) children experienced an asymptomatic drop in platelets in the first week after treatment that recovered without intervention. Of the 19 children with repeated outcome assessments, 11% (n = 2) experienced stabilization and 89% (n = 17) experienced improvement in motor function. CONCLUSIONS: In this population, with thorough screening and careful post–gene transfer management, replacement therapy with onasemnogene abeparvovec-xioi is safe and shows promise for early efficacy." @default.
• W3080552198 created "2020-09-01" @default.
• W3080552198 creator A5005401162 @default.
• W3080552198 creator A5015934254 @default.
• W3080552198 creator A5035271470 @default.
• W3080552198 creator A5036920096 @default.
• W3080552198 creator A5039453462 @default.
• W3080552198 creator A5040469939 @default.
• W3080552198 creator A5041763238 @default.
• W3080552198 creator A5044594977 @default.
• W3080552198 creator A5047212225 @default.
• W3080552198 creator A5047809221 @default.
• W3080552198 creator A5047869585 @default.
• W3080552198 creator A5048998234 @default.
• W3080552198 creator A5049982214 @default.
• W3080552198 creator A5050452664 @default.
• W3080552198 creator A5050919294 @default.
• W3080552198 creator A5062520190 @default.
• W3080552198 creator A5079060025 @default.
• W3080552198 creator A5090389497 @default.
• W3080552198 date "2020-09-01" @default.
• W3080552198 modified "2023-10-05" @default.
• W3080552198 title "Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes" @default.
• W3080552198 cites W1876029662 @default.
• W3080552198 cites W1980537418 @default.
• W3080552198 cites W2032902046 @default.
• W3080552198 cites W2045117117 @default.
• W3080552198 cites W2075859954 @default.
• W3080552198 cites W2099624163 @default.
• W3080552198 cites W2119878613 @default.
• W3080552198 cites W2147552101 @default.
• W3080552198 cites W2166739815 @default.
• W3080552198 cites W2273626464 @default.
• W3080552198 cites W2765253110 @default.
• W3080552198 cites W2765483614 @default.
• W3080552198 cites W2768938988 @default.
• W3080552198 doi "https://doi.org/10.1542/peds.2020-0729" @default.
• W3080552198 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32843442" @default.
• W3080552198 hasPublicationYear "2020" @default.
• W3080552198 type Work @default.
• W3080552198 sameAs 3080552198 @default.
• W3080552198 citedByCount "77" @default.
• W3080552198 countsByYear W30805521982020 @default.
• W3080552198 countsByYear W30805521982021 @default.
• W3080552198 countsByYear W30805521982022 @default.
• W3080552198 countsByYear W30805521982023 @default.
• W3080552198 crossrefType "journal-article" @default.
• W3080552198 hasAuthorship W3080552198A5005401162 @default.
• W3080552198 hasAuthorship W3080552198A5015934254 @default.
• W3080552198 hasAuthorship W3080552198A5035271470 @default.
• W3080552198 hasAuthorship W3080552198A5036920096 @default.
• W3080552198 hasAuthorship W3080552198A5039453462 @default.
• W3080552198 hasAuthorship W3080552198A5040469939 @default.
• W3080552198 hasAuthorship W3080552198A5041763238 @default.
• W3080552198 hasAuthorship W3080552198A5044594977 @default.
• W3080552198 hasAuthorship W3080552198A5047212225 @default.
• W3080552198 hasAuthorship W3080552198A5047809221 @default.
• W3080552198 hasAuthorship W3080552198A5047869585 @default.
• W3080552198 hasAuthorship W3080552198A5048998234 @default.
• W3080552198 hasAuthorship W3080552198A5049982214 @default.
• W3080552198 hasAuthorship W3080552198A5050452664 @default.
• W3080552198 hasAuthorship W3080552198A5050919294 @default.
• W3080552198 hasAuthorship W3080552198A5062520190 @default.
• W3080552198 hasAuthorship W3080552198A5079060025 @default.
• W3080552198 hasAuthorship W3080552198A5090389497 @default.
• W3080552198 hasBestOaLocation W30805521981 @default.
• W3080552198 hasConcept C114614502 @default.
• W3080552198 hasConcept C126322002 @default.
• W3080552198 hasConcept C161921814 @default.
• W3080552198 hasConcept C187212893 @default.
• W3080552198 hasConcept C2776715498 @default.
• W3080552198 hasConcept C2777910003 @default.
• W3080552198 hasConcept C2778045022 @default.
• W3080552198 hasConcept C2778558090 @default.
• W3080552198 hasConcept C2779134260 @default.
• W3080552198 hasConcept C2908647359 @default.
• W3080552198 hasConcept C33923547 @default.
• W3080552198 hasConcept C71924100 @default.
• W3080552198 hasConcept C90924648 @default.
• W3080552198 hasConcept C99454951 @default.
• W3080552198 hasConceptScore W3080552198C114614502 @default.
• W3080552198 hasConceptScore W3080552198C126322002 @default.
• W3080552198 hasConceptScore W3080552198C161921814 @default.
• W3080552198 hasConceptScore W3080552198C187212893 @default.
• W3080552198 hasConceptScore W3080552198C2776715498 @default.
• W3080552198 hasConceptScore W3080552198C2777910003 @default.
• W3080552198 hasConceptScore W3080552198C2778045022 @default.
• W3080552198 hasConceptScore W3080552198C2778558090 @default.
• W3080552198 hasConceptScore W3080552198C2779134260 @default.
• W3080552198 hasConceptScore W3080552198C2908647359 @default.
• W3080552198 hasConceptScore W3080552198C33923547 @default.
• W3080552198 hasConceptScore W3080552198C71924100 @default.
• W3080552198 hasConceptScore W3080552198C90924648 @default.
• W3080552198 hasConceptScore W3080552198C99454951 @default.
• W3080552198 hasIssue "3" @default.
• W3080552198 hasLocation W30805521981 @default.
• W3080552198 hasOpenAccess W3080552198 @default.
• W3080552198 hasPrimaryLocation W30805521981 @default.
• W3080552198 hasRelatedWork W2033399914 @default.
• W3080552198 hasRelatedWork W2062455150 @default.

• next